# Theranostics

Source: https://nuclide.cc/terms/theranostics/  
Nuclide record `theranostics` (Term). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Using the same targeting molecule for a diagnostic scan and a therapy, so you treat exactly what you can see.

## Summary

Theranostics uses the same targeting molecule for a diagnostic scan and for therapy, so clinicians treat exactly what they can see. The established pairs are gallium-68 or fluorine-18 PSMA imaging with lutetium-177 or actinium-225 PSMA therapy, gallium-68 DOTATATE with lutetium-177 DOTATATE, and iodine-123 with iodine-131, and one chemistry thereby enables patient selection, dosimetry and response assessment. The concept links the Radioligand therapy (beta emitters), Targeted alpha therapy and PSMA PET technologies with Somatostatin receptor PET, Radioiodine therapy and the pairings PSMA PET to PSMA radioligand therapy and SSTR PET to PRRT. It is referenced by the Prostate cancer, Thyroid cancer and Neuroendocrine tumours entries and by Clarity Pharmaceuticals.

## Fields

- Kind: Term
- Last checked: 2026-09-04
- Also known as: theranostic

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Theranostics
- Wikipedia: https://en.wikipedia.org/wiki/Theranostics

## Connected records

- isotopes: [Actinium-225](https://nuclide.cc/isotopes/ac-225/), [Fluorine-18](https://nuclide.cc/isotopes/f-18/), [Gallium-68](https://nuclide.cc/isotopes/ga-68/), [Iodine-123](https://nuclide.cc/isotopes/i-123/), [Iodine-131](https://nuclide.cc/isotopes/i-131/), [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- technologies: [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioiodine therapy and whole-body iodine scanning](https://nuclide.cc/technologies/radioiodine-therapy/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/), [Somatostatin receptor PET (68Ga/64Cu-DOTATATE)](https://nuclide.cc/technologies/sstr-pet/), [Targeted alpha therapy](https://nuclide.cc/technologies/targeted-alpha-therapy/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Prostate cancer](https://nuclide.cc/indications/prostate/), [Thyroid cancer](https://nuclide.cc/indications/thyroid/)
- targets: [CXCR4](https://nuclide.cc/targets/cxcr4/)
- drugs: [Gallium-68 DOTATATE (and Cu-64 DOTATATE)](https://nuclide.cc/drugs/ga68-dotatate/), [Illuccix (kit for Ga-68 gozetotide)](https://nuclide.cc/drugs/illuccix/), [Locametz (kit for Ga-68 gozetotide)](https://nuclide.cc/drugs/locametz/), [Radioactive iodine (I-131)](https://nuclide.cc/drugs/radioactive-iodine/)
- companies: [Clarity Pharmaceuticals](https://nuclide.cc/companies/clarity-pharmaceuticals/)
- institutions: [ANZUP Cancer Trials Group](https://nuclide.cc/institutions/anzup/), [Erasmus MC Cancer Institute](https://nuclide.cc/institutions/erasmus-mc/), [European Association of Nuclear Medicine](https://nuclide.cc/institutions/eanm/), [Inselspital, Bern University Hospital / University Cancer Center Inselspital](https://nuclide.cc/institutions/inselspital-bern/), [IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)](https://nuclide.cc/institutions/irst-meldola/), [Society of Nuclear Medicine and Molecular Imaging](https://nuclide.cc/institutions/snmmi/), [TUM Klinikum rechts der Isar / CCC München](https://nuclide.cc/institutions/tum-munich/)
- terms: [PRRT (peptide receptor radionuclide therapy)](https://nuclide.cc/terms/prrt-term/), [Radioiodine therapy (I-131)](https://nuclide.cc/terms/radioiodine-term/), [Theranostic pair](https://nuclide.cc/terms/theranostic-pair-term/)
- pairings: [PSMA PET → PSMA radioligand therapy](https://nuclide.cc/pairings/psma-pet-to-rlt/), [SSTR PET → PRRT](https://nuclide.cc/pairings/sstr-pet-to-prrt/)
- ideas: [Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes](https://nuclide.cc/ideas/idea-reg-regional-radiopharmacy-hubs/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://nuclide.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours](https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/), [Radiopharmaceutical therapy in cancer: clinical advances and challenges](https://nuclide.cc/key-papers/paper-sgouros-tat-review-nat-rev-2020/), [Radiotheranostics: a roadmap for future development](https://nuclide.cc/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)
- fronts: [Molecular imaging](https://nuclide.cc/fronts/f-molecular-imaging/)

---
JSON: https://nuclide.cc/api/v1/entities/theranostics.json